India Immunology Drugs Market to Grow with a CAGR of 7.08% through 2030
Increasing
prevalence of immunological disorders and innovative & new product launches
is expected to drive the India Immunology Drugs Market growth in the forecast
period, 2026-2030.
According
to TechSci Research report, “India Immunology Drugs Market - By Region, Competition, Forecast & Opportunities, 2020-2030F”, the
India Immunology Drugs Market stood at USD 2.65 Billion in 2024 and
is anticipated to grow with a CAGR of 7.08% through 2030.
The India Immunology Drugs Market is primarily
driven by several key factors. The increasing prevalence of immunological
disorders, such as rheumatoid arthritis and multiple sclerosis, is one major
driving force.
India's
robust pharmaceutical industry and its capacity for high-volume generic drug
production contribute significantly to market growth. Advances in biologic drug
development and a growing understanding of immunological diseases have also
allowed for more targeted and effective therapies, further propelling market
expansion. Increased healthcare expenditures and a growing awareness about
immunological disorders among the public are also contributing to the growth of
this market.
India,
with its vast population and burgeoning middle class, presents a significant
and lucrative market for immunology drugs. These drugs, specifically designed
to modulate the immune system, play a pivotal role in the treatment of various
diseases, including autoimmune disorders, infectious diseases, and cancers.
Over the past decade, the Indian immunology drugs market has witnessed
exponential growth, fueled by expanding healthcare infrastructure and improved
access to medical services.
Both
established pharmaceutical giants and emerging local companies are making
notable inroads into this promising market. Several factors contribute to its
growth, including the increasing awareness about autoimmune diseases, rising
healthcare expenditure, and the advent of biosimilars. The prevalence of
immunology-related diseases, such as rheumatoid arthritis, psoriasis, and
Crohn’s disease, has been on the rise, further driving the demand for these
drugs. However, challenges persist in the form of the high cost of immunology
drugs and the complexity associated with drug development. The pricing of these
medications often renders them unaffordable for the average Indian consumer,
limiting access. The development of new drugs requires substantial resources
and time, making it a high-risk endeavor for market players.
Nonetheless,
the advent of biosimilars, which are essentially more affordable versions of
biologic drugs, has the potential to disrupt the market and increase
accessibility. Indian pharmaceutical companies, leveraging their expertise in
generic drugs, are at the forefront of biosimilar development, contributing to
the market's dynamics.
The
Indian government's focus on improving healthcare infrastructure and making
healthcare more affordable presents a unique opportunity for the immunology
drugs market. Policies such as Ayushman Bharat, the world's largest
government-funded healthcare program, are expected to drive the demand for
these drugs. The COVID-19 pandemic has further highlighted the critical role of
immunology in disease management and prevention, amplifying the spotlight on
immunology drugs. This has resulted in increased awareness and demand, further
bolstering the market's growth prospects.
While
the Indian immunology drugs market faces certain obstacles, the overall outlook
remains positive. With continued investment in healthcare and the surge in the
development of biosimilars, the market is poised for substantial growth in the
coming years. Despite the challenges, the potential of the Indian immunology
drugs market is immense, and its strategic importance on the global stage is
indisputable. The continuous exploration of innovative solutions and
collaborations will be instrumental in unlocking its full potential.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on "India
Immunology Drugs Market”
India Immunology Drugs Market is segmented into drug class, indication, end
user, regional distribution, and company.
Based
on end user, hospitals, being the primary healthcare facilities, play a crucial
role in the administration and usage of immunology drugs. With their extensive
reach and capacity to cater to a large number of patients, hospitals experience
a higher demand and consumption of immunology medications. This is mainly due
to the fact that hospitals are equipped with specialized medical professionals
and advanced infrastructure, making them ideal for the treatment and management
of various immunological conditions. In addition to providing comprehensive
medical care, hospitals often collaborate with research institutes and
pharmaceutical companies to stay updated with the latest advancements in
immunology. This ensures that patients receive the most effective and
innovative therapies available.
Hospitals
serve as important hubs for clinical trials and research studies related to
immunological disorders. These collaborations contribute to the development of
new drugs and therapies, further expanding the treatment options available to
patients. The close association between hospitals and research institutes also
fosters a culture of continuous learning and knowledge exchange among
healthcare professionals. Hospitals & clinics hold a significant position
in the Indian immunology drugs market. Their extensive reach, specialized
expertise, and collaborations with research institutes and pharmaceutical
companies make them pivotal in delivering effective and innovative immunology
treatments to patients.
Based
on region, West India shows the significant growth for Indian Immunology Drugs
Market due to several factors. The region's dense population, combined with
various environmental and lifestyle factors, leads to a greater prevalence of
immunological disorders, thereby increasing the demand for immunology drugs.
This includes factors such as pollution, stress, and dietary patterns that
contribute to the higher incidence of these disorders. There is a high level of
healthcare infrastructure and medical facilities in this region, ensuring
better access to these drugs. The presence of well-established hospitals,
research centers, and pharmaceutical companies further supports the
availability and distribution of immunology drugs.
Major
companies operating in India Immunology Drugs Market are:
- Panacea
Biotec Ltd.
- Bristol-Myers
Squibb India Pvt Ltd.
- Wockhardt
Ltd.
- Pfizer
Ltd.
- Sanofi
India Ltd.
- GlaxoSmithKline
Pharmaceuticals Ltd.
- Abbott
India Ltd.
- Genetech
Pvt Ltd.
- Novartis
India Ltd.
- Allergan
India Pvt Ltd.
Download
Free Sample Report
Customers
can also request for 10% free customization on this report
“Biologics
have brought about a transformative shift in the immunology landscape, offering
precise, targeted therapies that are more effective in treating a range of
autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s
disease, and multiple sclerosis. These drugs, derived from living organisms,
are designed to interact with specific molecules or cells within the immune
system to modulate its activity, which provides better management of chronic
conditions and reduces the occurrence of side effects typically seen with
traditional therapies. In India, the adoption of biologics has gained
significant momentum, thanks to breakthroughs in biotechnology that enable the
production of more advanced and effective treatments. The country's improvement
in manufacturing capabilities, especially with the rise of contract
manufacturing organizations (CMOs), has facilitated the availability of
high-quality biologic drugs at competitive prices. Additionally, the increasing
burden of autoimmune diseases in India, driven by both lifestyle factors and an
aging population, has led to a higher demand for biologic treatments. One of
the most notable classes of biologics is monoclonal antibodies, which are
gaining popularity due to their precision in targeting specific disease-causing
components. This specificity results in more effective treatment with fewer
adverse effects compared to traditional small molecule drugs”, said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“India Immunology Drugs Market By Drug Class (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication, Others), By Indication (Arthritis, Plaque Psoriasis, Spondylitis, Inflammatory Bowel Disease, Transplant Rejection, Others), By End User (Hospitals & Clinics, Cancer Research Institute, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future
growth potential of India Immunology Drugs Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in India Immunology Drugs Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com